Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
| Revenue (TTM) | $2.37B |
| Gross Profit (TTM) | $1.73B |
| EBITDA | $83.42M |
| Operating Margin | -7.90% |
| Return on Equity | -2.66% |
| Return on Assets | 0.60% |
| Revenue/Share (TTM) | $10.46 |
| Book Value | $1.93 |
| Price-to-Book | 15.69 |
| Price-to-Sales (TTM) | 2.86 |
| EV/Revenue | 3.115 |
| EV/EBITDA | 196.43 |
| Quarterly Earnings Growth (YoY) | -17.40% |
| Quarterly Revenue Growth (YoY) | 3.80% |
| Shares Outstanding | $223.08M |
| Float | $210.59M |
| % Insiders | 5.51% |
| % Institutions | 70.49% |
Volatility is currently expanding
The FTC alleged Hims & Hers shared sensitive user health information with advertisers including Meta and Snap through tracking technologies without proper consent. Regulators also accuse the telehealth company of charging customers for prescriptions before provider consultations and making subscriptions difficult to cancel.
2.6 million. That's how many people subscribe to Him & Hers for personal health, skin care, hair loss treatments and weight-loss management, according to the company's first quarter results, up 9% year-over-year.
The U.S. Federal Trade Commission is suing Hims & Hers alleging the telehealth platform shared users' health data with online advertisers despite promising privacy and engaged in deceptive billing and cancellation practices, an FTC spokesperson said.
Hims & Hers is a subscriber-based online healthcare provider that operates outside of the traditional paradigm. Its AI-native processes and visibility to each patient's full medical journey create a flywheel that's difficult for competitors to replicate. Its moat is further enhanced by its vertical integration and scale.
Hims & Hers Health is upgraded from "Hold" to "Buy," driven by operational discipline and strategic opportunism despite sector volatility. HIMS leverages FDA panel momentum on peptides, expanding into personalized treatments while maintaining a robust telehealth platform and global reach. Management pursues a "best in market" approach to peptide launches, prioritizing clinical rigor, validated supply chains, and data transparency over speed.
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health is set to tap what analysts estimate could be a multi-billion-dollar market for peptides if U.S. regulators loosen manufacturing restrictions.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced its Chief Accounting Officer, Irene Becklund will depart the company after more than seven years, effective October 9, 2026. Becklund will then serve as an advisor to the company for several months to assist with the transition. The company will conduct a search for her permanent successor, with Yemi Okupe, CFO of Hims & Hers, assuming the responsibilities of.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, refe.
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HIMS and any ticker you trade — then tracks every position and per-strategy win rate.
